top of page

Free Biopharma Daily Stock Updates - 06/30/22

$XBI $74.27 | -0.71%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.


Table of Contents:


Covid Updates

#HGEN -4% NIH/NIAID Locks ACTIV-5/BET-B Database. source


#VXRT -1% Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model. source


Pipeline Updates

#EVFM +15% Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO. source


#HRTX -12% Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability. source


#NMTR -22% 9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome. source


#NMTR -22% 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome. source


#RPHM +14% Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022). source


#DARE -2% Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis. source


#SCPH -2% scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients. source


#NRIX +2% Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites. source


#CARA -5% Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica. source


#TALS -37% Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update. source


#EVAX -4% Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target. source


#CDAK -21% Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™. source


#ANGN -33% (6/29) Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease. source


#ENDP -11%


#BLPH -14%


#LXRX -17% (6/29) Lexicon Announces Positive Top-line Results from Phase 2 Proof-of-Concept Study of LX9211 in Painful Diabetic Neuropathy. source


#PRVB +2% Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022. source


#AKBA -7% Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka. source


#AMRN -18% REDUCE-IT EXPLORATORY POST HOC BIOMARKER SUB-ANALYSIS SHOWS RELATIVELY SMALL CHANGES IN INFLAMMATORY MARKERS BETWEEN ICOSAPENT ETHYL AND PLACEBO. source


#CLDX -3% Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022. source

 

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

 

Business Updates

#MCRB +9% Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock. source


#BPMC -3% Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma. source


#VRCA -12% Verrica Announces Pricing of Public Offering of Common Stock. source


#AFMD -1.5% Affimed Establishes Scientific Advisory Board - Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology.


#GERN +2% Geron Corporation Announces Expansion of Existing Loan Facility. source


#XFOR +10% X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months. source

 

Posted by FS/DV

0 comments

Comments


bottom of page